Condition: Prostate Cancer · Sponsor: Medical University of Bialystok
The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment
This description comes directly from the study's public registry record.
Ewa Sierko, Professor · 85 664 67 83 · ewa.sierko@iq.pl
Clinical Research Support Center Medical University of Bialystok · 85 686 53 86
Always discuss trial participation with your own doctor first.
| Białystok Oncology Center Maria Skłodowska-Curie | Bialystok, Poland | Recruiting |
| University Clinical Hospital in Białystok | Bialystok, Poland | Recruiting |
| Independent Public Health Care Center of the Ministry of Internal Affairs and Administration in Białystok | Bialystok, Poland | Not Yet Recruiting |
| Laboratory of Molecular Imaging and Technology Development | Bialystok, Poland | Recruiting |
| Oncology Center named after prof. F. Łukaszczyk in Bydgoszcz | Bydgoszcz, Poland | Recruiting |
| Provincial Multidisciplinary Center of Oncology and Traumatology named after M. Copernicus University in Łódź | Lodz, Poland | Not Yet Recruiting |
| Center of Oncology of the Lublin Region St. Jana z Dukli | Lublin, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05582876